|
IL256201D0
|
|
Composition comprising highly-concentrated alpha-1-proteinase inhibitor and method for obtaining thereof
|
|
US9598739B1
|
|
Human erythrovirus
|
|
US2015267268A1
|
|
Methods, compositions, and kits for determining human immunodeficiency virus (HIV)
|
|
AU2012304839A1
|
|
Methods, compositions, and kits for determining Hepatitis A Virus
|
|
CN103781908A
|
|
Compositions, methods, and kits for nucleic acid hybridization
|
|
CN103635575A
|
|
Methods, compositions, and kits for determining human immunodeficiency virus (HIV)
|
|
AU2011306651A1
|
|
Immunochromatography devices, methods and kits
|
|
MX2012009510A
|
|
Therapeutic delivery devices, systems, and methods.
|
|
HUE037733T2
|
|
Lyophilization methods, compositions, and kits
|
|
CN102655876A
|
|
Composition, method, and kit for alpha-1 proteinase inhibitor
|
|
HUE025670T2
|
|
Methods for preparing plasminogen
|
|
KR20160110544A
|
|
Composition, method and kit for preparing plasmin
|
|
AU2009236305A1
|
|
Two-stage ultrafiltration/diafiltration
|
|
EP2215265A2
|
|
Method for adjusting results of a polymerase chain reaction (pcr) instrument
|
|
EP1981540A2
|
|
Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
|
|
ME01263B
|
|
Recombinantly modified plasmin
|
